Mon, 27 May 2024 Today's Paper

Southeast Asia's top drugmaker eyes SL

2 February 2018 11:03 am - 6     - {{hitsCtrl.values.hits}}

A A A

PT Kalbe Farma, whose antacid drug Promag is a household name in Indonesia, is seeking a partner in Sri Lanka and eyeing the Middle East as a new market for its nutritional products.

The pharmaceutical company, Southeast Asia’s biggest, will initially export its products to Sri Lanka before joining hands with a local company to manufacture its generic drugs, President Director Vidjongtius said in an interview in Jakarta on Tuesday. It’s also expanding to the Middle East after the positive response to test-marketing of its packaged coconut water, he said.

Kalbe, which started out from a garage in Jakarta five decades ago, derives about 94 percent of its sales from the local market with prescription drugs, consumer health and nutritional products. As local sales remain sluggish, the Jakarta-based company is focusing on new markets to broaden its reach beyond Southeast Asia, Vidjongtius said.

“Our focus has been Asean so far and we have been quite successful,” said Vidjongtius, who took over as the president director in June 2017. “Our ultimate mission is to develop a portfolio for the developed and more regulated countries like the U.S. and Europe. We are upgrading our quality standards to global level.”

Kalbe is “more optimistic” about the outlook for sales and profit this year than in 2017 as it starts selling new products and targets more markets, Vidjongtius said. The company probably ended 2017 with revenue and profit growth of about 4 percent to 5 percent, he said, ahead of the release of its full-year audited earnings.

The outlook for Kalbe remains challenging in the short term, said Vanessa Karmajaya, an analyst at Yuanta Securities Indonesia.

“For energy drinks, the market is getting saturated due to perceived health concerns,” Karmajaya said. “Exports and imports of drugs are getting highly regulated so it would be tough for them to grow this segment. They have diversified into a new segments like dialysis and supplying medical consumables and these markets in the longer term could be positive.”

Kalbe, which gets about a third of its revenue from distribution and logistics, is open to roping in an equity partner for the unit, Vidjongtius said. The subsidiary, PT Enseval Putera Megatrading, has presence in 53 Indonesian cities and derives about 30 percent of its revenue from third parties. (bloomberg)


  Comments - 6

  • Lal Friday, 02 February 2018 12:13 PM

    Many poor Asian countries picked up the Pharma indistry to create jobs for Bio-chem grads but SL is several decades behind. Better late than never I guess

    SL Friday, 02 February 2018 03:01 PM

    when investment proposals are tabled ,minister's first question is his portion before approving the project.It is a well known fact that we've lost so many investments due to these idiots

    sss Friday, 02 February 2018 04:57 PM

    more relevant is we have had medical education for half a century and nothing to show for biotech industry

    Druggist Saturday, 03 February 2018 08:34 AM

    We have so many drug makers in SL, !!!

    Raj Friday, 02 February 2018 09:36 PM

    We are Sri Lankans ,we worship the doctors,why we need these drug making companies. The most important people are the doctors.

    Mm Saturday, 03 February 2018 07:03 AM

    Raj, I feel sorry for you. You are one of those less educated fools who think doctors are God’s. They are book memorizing greedy fools.


Add comment

Comments will be edited (grammar, spelling and slang) and authorized at the discretion of Daily Mirror online. The website also has the right not to publish selected comments.

Reply To:

Name - Reply Comment